The damage can lead to both sudden “flares” of inflammation and a slow worsening of symptoms over time. Historically, MS has been broken down into specific subtypes, as detailed below. But the reality ...

Early intervention and effective therapies are transforming multiple sclerosis management, enhancing patient outcomes, and delaying disability progression.

Two Phase 3 trials testing the investigational oral therapy fenebrutinib in people with multiple sclerosis (MS) have hit ...

Discover how cladribine compares to S1P modulators in treatment-naive relapsing-remitting MS, keep reading to learn more.

Fenebrutinib shows promise as the first BTK inhibitor for both RMS and PPMS, reducing relapses and slowing disability progression. The FENhance 2 study demonstrated fenebrutinib's efficacy over ...

SUDO-550, an oral therapy for MS, was found to be safe and to reach the brain in its first human clinical trial, trial ...

Roche has reported wins for its BTK inhibitor fenebrutinib in a pair of phase 3 studies across two multiple sclerosis (MS) populations. One victory was based on the finding that the candidate was ...

Cabaletta Bio, Inc. (($CABA)) announced an update on their ongoing clinical study. RESET-MS is a Phase 1/2 open-label study conducted by Cabaletta ...

Share on Pinterest A recent study reports that starting treatment at the first signs of MS symptoms could help slow disease progression. Jennifer Blount/Getty Images A recent study finds getting ...

Roche Holding AG said a multiple sclerosis drug showed it could work for most forms of the disease in two late-stage trials, ...

Doctors are looking to recruit more people for the trial, which they say could one day be given as a single one-off treatment ...

A biology teacher and mother-of-two has become the first UK patient to receive a "gamechanger" therapy to treat multiple ...